IMAX Corporation (IMAX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $47.36, IMAX Corporation (IMAX) is priced for today's economics sustained for ~6.7 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/IMAX

Headline

FieldValue
TickerIMAX
CompanyIMAX Corporation
Current price$47.36/sh
CompositionContent Solutions 38% / Technology Products and Services 62%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)10.2%
Operating margin today19.1%
Margin compression (value-band)-8.9pp
Must persist for6.7y
Multiple paid35x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.26σ
cohort percentile (of 190 peers)62
sustained it ~6.7 years at this level23%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset5.98x4expensive
Earnings3.16x5expensive
Relative2.05x5expensive
Growth0.74x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.4%); the inversion above states its own rate.

Per-Model Detail (n=17)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$66.760.71xyesFCF base $0.1B, growth 12% (input: historical growth), terminal g 4.0%, WACC 8.4%, 6yr projection
DCF Exit MultipleGrowth$63.650.74xyesExit EV/EBITDA: 33.3x / 35.3x / 37.3x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$24.861.91xyesP/E 33.79x (blended: static sector reference 18x + trailing (TTM) 71x), scenarios: 28.0x / 33.8x / 39.5x (bear / base = reference held flat / bull), EV/EBITDA 18.98x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$7.256.53xyesBV/sh $6.12, ROE (TTM) 11.0%, ke 9.3%
Two-Stage Excess ReturnAsset$7.866.03xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$47.411.00xyesRev $0.4B, growth 12% (input: historical growth; tapered), Terminal P/S: 5.3x / 6.4x / 7.5x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$23.102.05xyesEPS $0.66, growth 35% (input: historical EPS growth), PEG=2.02 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$4.5810.34xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.04B × (1−29%) / WACC 8.4% → EPV (no growth)
Residual IncomeAsset$7.985.93xyesBV $6.12 + 5yr PV of (ROE (TTM) 11.0% − Kₑ 9.3%) × BV; BV grows 7.1%/yr
Graham NumberAsset$9.534.97xyes√(22.5 × EPS $0.66 × BVPS $6.12) — Graham's conservative floor
EV/EBITDA RelativeRelative$14.523.26xyesEBITDA $0.08B × sector EV/EBITDA 12.0x
FCF YieldEarnings$20.342.33xyesFCF $115.5M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$14.993.16xyesSBC-adj FCF $0.09B (FCF $0.12B − SBC $0.03B) capitalized at Kₑ
Ben Graham FormulaEarnings$21.302.22xyesEPS $0.66 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$1.1142.67xyesBV $6.12 × (ROIC 1.5% / WACC 8.4%) (excluded from median)
P/Sales SectorRelative$18.452.57xyesRevenue $0.40B × sector P/S 2.5x
PEG Fair ValueRelative$24.751.91xyesEPS $0.66 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$7.146.63xyesEPS $0.66 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$98.1m
Net debt / NOPAT (after-tax)1.77x
Net debt / operating income (pre-tax)1.27x
Interest coverage10.4x
Share count CAGR (buyback)-0.9%
Burning cashno

Bullet Takeaways

Bull Case

The direction of every number that matters is up, and the momentum is the bull case. IMAX closed 2025 with a record $1.28 billion global box office, up 40% from the prior year and 13% above its pre-pandemic 2019 record, with all three regions setting marks: North America $449 million, China $407 million, and rest of world $427 million. Operating margin runs near 19% and the company throws off real cash, so this is not a recovering business limping back; it is one printing the best results in its history. When revenue, margins, and cash flow are all moving in the same direction off a record base, the burden shifts to the bears to explain why the trend reverses.

The network is what makes that box office recurring rather than one-time. IMAX does not own theaters; it places its systems with cinema operators and earns a share of every ticket sold on those screens. Its filing describes the structure: systems are provided "to customers through joint revenue sharing arrangements", so a single installed system generates a stream of box-office-linked revenue for years. The footprint keeps expanding: 1,864 systems in 91 countries at the end of 2025, with 160 installed during the year, up 10% from 2024, and a backlog of 434 systems still to come. Each new system is a new annuity on the box office, and the backlog is visibility on growth the company has already signed.

The most underappreciated driver is local-language content. IMAX's 2025 local-language box office reached $405 million, 66% above the prior record, on the largest slate in its history, 67 international films from 14 countries. This matters because it loosens IMAX's historical dependence on the Hollywood release calendar: a strong year in Japanese, Chinese, or Indian cinema can now fill the screens when the studio slate is thin. Management guides the local-language slate to 75 titles in 2026 and total box office to about $1.4 billion, another record. The bull case is a capital-light network operator with expanding screens, a diversifying content engine, and momentum at an all-time high.

Bear Case

The fragile assumption baked into the price is that a record year is a new baseline rather than a peak. At about $44 (June 27, 2026) the market values IMAX at roughly 36 times operating income, embedding growth at the company's self-funding ceiling for about seven years. That assumption rests on 2025's $1.28 billion box office, up 40% in a single year, being extended and built upon. But box office is hit-driven. A blockbuster-heavy slate produces a year like 2025; a thin or poorly received slate produces a weak one, and IMAX does not control which films get made or whether they connect with audiences. The company's own accounting reflects how much rests on the films: it estimates variable consideration using "average historical box office results, eliminating significant outliers", an acknowledgment that the revenue swings with the slate. The price assumes the swings keep breaking favorably for the better part of a decade, which only about one in five comparable fast-growers has managed.

The second dependency is the studios and the theatrical window itself. IMAX's screens are filled by films from Hollywood and increasingly from international producers, but the structural pressure on the theatrical model has not gone away: streaming has compressed windows and changed how studios think about which films deserve a wide cinema release. A year where the major studios pull back on the kind of spectacle that drives premium-format demand would hit IMAX directly, because its differentiated experience matters most for exactly the big-budget films that are most exposed to a streaming-first strategy. The local-language expansion diversifies this, but it does not eliminate it; the largest box-office dollars still come from the tentpole releases.

The valuation gives those risks no cushion. Every static method lands below the price: asset-based approaches put fair value far below, earnings-power and peer-multiple methods sit well under it, and only the growth-driven cash-flow method, the one that carries the record year forward, reaches the current level. When a single growth-dependent family is the only one that justifies the price, the price is a pure durability bet. The balance sheet is fine, net debt is about $98 million against operating income, with interest covered more than ten times, so this is not a solvency concern. The bear case is narrower and harder to dismiss: IMAX is a good business priced as if its best year ever is the floor, when the history of the box office says strong years and weak years alternate, and a single soft slate would collapse the multiple toward where the other methods sit.

Valuation

The price is paying for the record to continue. At about $44 IMAX trades near 36 times operating income, and inverting that says the market expects operating growth held at the company's self-funding ceiling for roughly seven years. The near-term rate is within what IMAX has just delivered, so the question is duration rather than peak pace, and only about one in five comparable fast-growers has sustained that rate for seven years. The complication specific to IMAX is that the recent rate sits on a record $1.28 billion box-office year, so the price is extrapolating from a high-water mark rather than a normalized base.

The methods we use to triangulate are unanimous on direction. Asset-based methods land far below the price, because IMAX's capital-light model means there is little book value to anchor to. Earnings-power approaches, which capitalize current profit without much growth, sit well below. Peer-multiple methods land under the price too, though the cohort here, precision-instrument and industrial-technology companies, is an imperfect comp for a premium-cinema network operator, so it is a directional rather than a precise read. Only the growth-driven cash-flow method reaches the price, by carrying the recent growth forward. That pattern, where only the forward-growth family gets there, marks the premium as a bet on durable compounding that the static frames cannot price; for IMAX, that compounding depends on the box office and the install base both staying on their current trajectory.

Solvency is not the issue. Net debt of about $98 million is roughly 1.3 times a year's operating income, interest coverage runs above ten times, and the share count has edged lower. The balance sheet comfortably supports the business through a weak film year. What bounds the downside is therefore not leverage but the gap between the price and where the cycle-independent methods land. The buyer at this price is underwriting a premium-format network at a multiple that needs the box office to keep setting records and the installation pace to hold, with a 434-system backlog as visible growth and a hit-driven content cycle as the swing variable.

Catalysts

The headline catalyst is the record itself. IMAX closed 2025 with $1.28 billion in global box office, up 40% year over year and 13% above its 2019 record, with regional records of $449 million in North America, $407 million in China, and $427 million in the rest of the world. The network reached 1,864 systems across 91 countries, with 160 installed during the year, up 10% from 2024, and a backlog of 434 systems. Local-language content was the standout, reaching $405 million in box office, 66% above the prior record, from a slate of 67 international films across 14 countries.

The forward path is mapped in the 2026 guidance: approximately $1.4 billion in global box office, which would be another record, alongside 160 to 175 system installations and a local-language slate expanding to 75 titles. The events to watch are the actual film slate landing through the year, because the box-office number depends on which titles release and how they perform, and the quarterly installation count, which converts the backlog into recurring revenue. A strong Hollywood and international lineup pushes IMAX toward the guidance; a thin or underperforming slate is the most direct risk to it.

Peer Cohorts (Per Segment, With Filing Citations)

Content Solutions (reported)

Technology Products and Services (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

IMAX FY2025 results, 10-K · IMAX 2026 guidance · IMAX FY2025 results, press release · IMAX 2025 commentary

View the full interactive IMAX report on boothcheck